@article {NANNI211, author = {UMBERTO NANNI and PATRIZIA FERRONI and SILVIA RIONDINO and ANTONELLA SPILA and MARIA GIOVANNA VALENTE and GIROLAMO DEL MONTE and MARIO ROSELLI and FIORELLA GUADAGNI}, title = {Biospecimen Digital Twins: Moving from a {\textquotedblleft}High Quality{\textquotedblright} to a {\textquotedblleft}Fit-for-Purpose{\textquotedblright} Concept in the Era of Omics Sciences}, volume = {20}, number = {3}, pages = {211--221}, year = {2023}, doi = {10.21873/cgp.20376}, publisher = {International Institute of Anticancer Research}, abstract = {The growing demand for personalized medicine we are currently witnessing has given rise to more in-depth research in the field of biomarker discovery and, thus, in biological banks that hold the ability to process, collect, store, and distribute {\textquotedblleft}high-quality{\textquotedblright} biological specimens. However, the notion of {\textquotedblleft}specimen quality{\textquotedblright} is subject to change with technological advancements. In this perspective, we propose that the notion of sample quality should shift from a broad definition of {\textquotedblleft}high-quality{\textquotedblright} to a {\textquotedblleft}fit-for-purpose{\textquotedblright} concept more suitable for precision medicine studies. Digital twins are a digital replica of real entities. These are largely adopted in any digitalized domain and are currently finding applications in biomedicine. The adoption of digital twins for biosamples, proposed in this paper, can provide prompt information about the whole lifecycle of the physical twin (i.e., the biosample) and substantially extend the possible matching criteria between the available samples and the researchers{\textquoteright} and physicians{\textquoteright} requests. This fine-tuning matching could greatly contribute to improving the {\textquotedblleft}fit-for-purpose{\textquotedblright} quality, not only for studies based on current needs, but also to improve the identification of the best available samples in future situations, determined by the evolution of technologies and biosciences. Assuming and exploiting a data-science view in our biobank perspective, the more (accurate) data there are available, the more information can be extrapolated from them, the more opportunities there are for matching future, currently unknown, needs. This should be a mandatory principle that the {\textquoteleft}time machines{\textquoteright} called biobanks should follow.}, issn = {1109-6535}, URL = {https://cgp.iiarjournals.org/content/20/3/211}, eprint = {https://cgp.iiarjournals.org/content/20/3/211.full.pdf}, journal = {Cancer Genomics \& Proteomics} }